Full-Time
Senior Technical Program Manager
Enterprise Software & Clinical Solutions
Posted on 1/23/2026
Q Bio
11-50 employees
Subscription-based preventive health assessments and monitoring
Compensation Overview
$180k - $250k/yr
San Carlos, CA, USA
In Person
 Business & Strategy (1) |
|---|
- Experience-7+ years of technical program management experience in regulated environments .At least 3 years supporting Software as a Medical Device (SaMD) or enterprise health-tech platforms.
- SDLC & Quality Systems Fluency- Deep experience with modern SDLC practices and strong working knowledge of ISO 13485 and IEC 62304 in agile, high-velocity environments.
- Compliance & Security Awareness- Familiarity with clinical workflows and data privacy/security frameworks including HIPAA, ISO 27001, and HITRUST, sufficient to anticipate risks and drive cross-functional alignment.
- Operating Profile- Experience combining large-company rigor with early-stage execution, including building structure where little exists.
- Mindset- High-agency, sleeves-up operator with a bias toward action, accountability, and follow-through. Passion for improving healthcare outcomes through disciplined execution in fast-moving environments.
- End-to-End Delivery & Deployment-Own program execution from requirements definition through development, validation, and delivery into production for enterprise clinical environments. Coordinate deployment across hospital systems, clinic networks, and other enterprise customers, including international rollouts.
- Release, Deployment & Readiness Management-Lead release readiness and deployment execution across engineering, quality, security, clinical operations, and regulatory stakeholders. Ensure releases meet clinical, operational, and compliance standards and integrate effectively into real-world clinical workflows.
- Program-Level Compliance Oversight-Coordinate and track regulatory and compliance activities (e.g., SaMD documentation, validation activities, clinical or technical programs) required for program delivery, ensuring readiness, completeness, and alignment across all contributing teams.
- Proactive Risk Management- Maintain a rigorous program-level risk management process, identifying technical, operational, and regulatory risks early and driving mitigations to closure.
- Operational Efficiency & Execution Cadence- Facilitate focused internal and external execution forums. Create and maintain program documentation to ensure visibility across all stakeholders. Publish concise weekly executive readouts highlighting progress, risks, decisions needed, and action-item closure—while minimizing unnecessary meeting overhead for delivery teams.
- Lead Distributed & Partner Teams- Drive execution across remote internal teams and external consultants, vendors, and partners.
- Governance, Process & System Building- Define and evolve delivery processes, reporting frameworks, and oversight structures appropriate for a scaling, regulated environment. Strengthen execution systems over time to support consistency, predictability, and sustainable delivery as the organization grows.
Q.bio provides preventive health care through a subscription model, offering ongoing health assessments like the Q Exam. The Q Exam, about one hour at a Q Center, collects data from blood, saliva, urine, vitals, and whole-body MRI, stored in a BioVault and accessible via a web-based Q Dashboard for telemedicine with doctors, trainers, nutritionists, and other professionals. It differentiates itself by combining multi-source data and an integrated dashboard to identify early signs of disease before symptoms appear, enabling timely interventions for both individuals and clinicians. The goal is to shift healthcare from reactive treatment to proactive, data-driven prevention by giving users continuous, actionable health information and enabling collaboration with healthcare providers.
Company Size
11-50
Company Stage
Late Stage VC
Total Funding
$67M
Headquarters
San Carlos, California
Founded
2015
Simplify's Take
What believers are saying
- Preventive healthcare market expanding as employers and insurers prioritize early disease detection.
- Subscription model with clinician partnerships creates recurring revenue and sticky customer relationships.
- FDA-cleared Constellation software and Gemini Dashboard enable longitudinal health monitoring for personalized medicine.
What critics are saying
- Prenuvo's 15+ established MRI centers undercut Q Bio's first-mover advantage in preventive screening.
- FDA may halt Mark I rollout citing overdiagnosis risks similar to Ezra's regulatory scrutiny.
- Open-source MRI-QAMPER toolkit replicates TFM quantification for free, commoditizing Q Bio's proprietary software.
What makes Q Bio unique
- Tensor Field Mapping delivers quantitative, harmonized MRI data across machines for AI diagnostics.
- Panomics approach integrates imaging, genetics, chemistry, vitals into unified Digital Twin health snapshot.
- Mark I full-body scanner captures 3,000 anatomical measurements in single scan versus multiple traditional scans.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -2%Q Bio has secured $27M in funding to advance its Mark I full-body MRI scanner. The investment includes new backer TELUS Global Ventures and existing investors like Khosla Ventures and Andreessen Horowitz. The Mark I scanner, utilizing Tensor Field Mapping technology, offers comprehensive data from 3,000 anatomical measurements in a single scan, eliminating the need for multiple scans.
Q Bio raises $27M in funding round for Mark I MRI scanner.
PALO ALTO, Calif.--(BUSINESS WIRE)--Q Bio Inc., an innovator in medical imaging technology, today announced the launch of Tensor Field Mapping (TFM), a new technology for Magnetic Resonance Imaging (MRI) that provides detailed insights into the human body that were previously unimaginable. Unlike traditional MRIs that provide qualitative data prone to machine or clinical variations, TFM delivers quantitative, harmonized imaging data that can be immediately accessed by AI to accelerate diagnostics. "For decades, MRI technology has been invaluable in diagnosing a wide range of medical conditions, yet it has been limited by its qualitative nature and the variability of the data," said Jeff Kaditz, Founder and CTO / CEO, Q Bio. "With the introduction of Tensor Field Mapping, we are taking a quantum leap forward, making multi-parametric quantification of tissues reproducible across machines, which is key to AI in MRI and personalized medicine.". TFM is the result of extensive research and development by Q Bio's team of experts in medical imaging, physics, and computational science, and will make its debut in the company’s upcoming Mark I full body scanner. The technology provides quantifiable data lacking in traditional MRIs so that properties of tissues can be measured and benchmarked on an ongoing basis
Q Bio launches multiparametric MRI quantification softwre.
Medical imaging company Q Bio announced the launch of a multiparametric MRI upgrade, dubbed Tensor Field Mapping (TFM), designed to provide more detail into the inner-workings of the human body than are currently possible with an MR scanner.